Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

Kaykay610 Aug. 13 at 12:46 AM

$ABCL https://youtu.be/SNlhN6nujIM?is=7iVa9xpWWxIoEvW1 Canada needs a champion

0 · Reply

Kaykay610 Aug. 13 at 12:16 AM

$ABCL ignore the noise

1 · Reply

Kaykay610 Aug. 13 at 12:06 AM

$ABCL im not going anywhere until the platform creates a lead molecule for each target,(ion channels, cd3, cd28, tri-specifics, degraders.. etc) 1 down 16 to go and only then will i sell my 6 shares

0 · Reply

Plan2TradeTrade2Plan Aug. 12 at 11:27 PM

$ABCL sold off 25% this morning at $9.45 and was hoping to buy the same or more under $9, based on last night's trading. It never happened, so I bought back at $9.88. Ooops.

0 · Reply

bdough44 Aug. 12 at 10:58 PM

$ABCL Bought at 3.8 and I’m out as of yesterday at 9.79. Looks like I got out a little early. Good luck to all.

2 · Reply

SnoddyTradz Aug. 12 at 10:25 PM

$ABCL Bulls on here bought 10s acting like it really did something 🤣🤣🤣 200m dilution hasn’t dropped yet! It will! So will SP🤣

0 · Reply

BlimpAbove Aug. 12 at 9:48 PM

$ABCL $VKTX and? Obviously his actions over there have turned into results. Who’s to say that this won’t happen at Viking now? Ignorant. Extremely

2 · Reply

JohnnyVacs Aug. 12 at 9:45 PM

$VKTX Neil Abuchon must be so happy with his move from $ABCL !!! 😂😂😂😂 Almost gone from Abcellera for 6 months and their stock price has almost tripled. His average in VKTX is $33.50😂😂😂😂😂

0 · Reply

psyxopathis Aug. 12 at 9:43 PM

$ABCL now that i got banned from all the bears, time to repeat my thesis about the stock and relax 😌. For me Abcl is zero to one company and it requires a lot of patience. I am extremely long and i am not interested to take any profits in the meantime. High risk still, even tho the p2 results imo derisked a lot the platform which is very positive to build the empire ABCL team trying to build. Good luck bulls, we have very long time ahead of us but the limit is literally the sky. ☘️

0 · Reply

SwingTrades1 Aug. 12 at 9:35 PM

$ABCL This is how I’m reading the tape: Slow, steady appreciation → solid bases at each level → HV compresses → shorts lose favorable entry points → increasing pressure to cover → potentially stronger upside as resistance gives way.

0 · Reply

AbCellera announces $200M common stock, warrants offering

Aug 11, 2026, 4:01 PM EDT - 1 day ago

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-08-11T13:35:37.000Z - 1 day ago

AbCellera price target raised to $30 from $12 at Truist

2026-08-10T19:55:32.000Z - 2 days ago

AbCellera price target raised to $25 from $13 at JonesResearch

Aug 10, 2026, 8:00 AM EDT - 2 days ago

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 7:30 AM EDT - 2 days ago

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 2 days ago

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 2 days ago

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:23 AM EDT - 2 days ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:13 AM EDT - 2 days ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

2026-08-10T11:11:27.000Z - 2 days ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

Aug 10, 2026, 7:00 AM EDT - 2 days ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 7, 2026, 4:30 PM EDT - 5 days ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

2026-08-06T12:20:50.000Z - 6 days ago

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:12:02.000Z - 6 days ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

Aug 5, 2026, 5:00 PM EDT - 7 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 7 days ago

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 7 days ago

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 7 days ago

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 7 days ago

AbCellera Reports Q2 2026 Business Results

2026-07-29T11:27:06.000Z - 14 days ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

Jul 29, 2026, 7:00 AM EDT - 14 days ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

2026-07-09T21:29:02.000Z - 4 weeks ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

Jul 7, 2026, 4:05 PM EDT - 5 weeks ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-07T10:35:14.000Z - 5 weeks ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

2026-07-06T13:15:29.000Z - 5 weeks ago

AbCellera apponts Lynn Seely to board of directors

LYEL

Jul 6, 2026, 9:00 AM EDT - 5 weeks ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jun 17, 2026, 7:43 AM EDT - 2 months ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jun 17, 2026, 7:00 AM EDT - 2 months ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

2026-06-05T13:05:56.000Z - 2 months ago

AbCellera appoints Victor Sandor to board of directors

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 4, 2026, 11:40 AM EDT - 2 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 3 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T10:58:11.000Z - 3 months ago

AbCellera price target raised to $8 from $7 at Stifel

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 3 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 1, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 4 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 4 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 5 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 6 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 7 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 7 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation

Jan 12, 2026, 9:00 AM EST - 7 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 8 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 8 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 1 year ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 2 years ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Kaykay610 Aug. 13 at 12:46 AM

$ABCL https://youtu.be/SNlhN6nujIM?is=7iVa9xpWWxIoEvW1 Canada needs a champion

0 · Reply

Kaykay610 Aug. 13 at 12:16 AM

$ABCL ignore the noise

1 · Reply

Kaykay610 Aug. 13 at 12:06 AM

$ABCL im not going anywhere until the platform creates a lead molecule for each target,(ion channels, cd3, cd28, tri-specifics, degraders.. etc) 1 down 16 to go and only then will i sell my 6 shares

0 · Reply

Plan2TradeTrade2Plan Aug. 12 at 11:27 PM

$ABCL sold off 25% this morning at $9.45 and was hoping to buy the same or more under $9, based on last night's trading. It never happened, so I bought back at $9.88. Ooops.

0 · Reply

bdough44 Aug. 12 at 10:58 PM

$ABCL Bought at 3.8 and I’m out as of yesterday at 9.79. Looks like I got out a little early. Good luck to all.

2 · Reply

SnoddyTradz Aug. 12 at 10:25 PM

$ABCL Bulls on here bought 10s acting like it really did something 🤣🤣🤣 200m dilution hasn’t dropped yet! It will! So will SP🤣

0 · Reply

BlimpAbove Aug. 12 at 9:48 PM

$ABCL $VKTX and? Obviously his actions over there have turned into results. Who’s to say that this won’t happen at Viking now? Ignorant. Extremely

2 · Reply

JohnnyVacs Aug. 12 at 9:45 PM

0 · Reply

psyxopathis Aug. 12 at 9:43 PM

0 · Reply

SwingTrades1 Aug. 12 at 9:35 PM

0 · Reply

Bullock3000 Aug. 12 at 8:46 PM

Lots of people disagreed while I was popping the $OPEN bubble. WoW was that profitable. Now it's $ABCL . Don't complain later.

3 · Reply

tiddyy Aug. 12 at 8:43 PM

$ABCL Currently not much value being assigned to the two other mystery programs. If Carl drops some information on ABCL688 we can see +$15 very soon, especially if the addressable market is massive, apparently Phase 1 starts in 2027, so it’s going to be soon This company is still completely undervalued for the data from ABCL635, just wait till the platform starts churning out more programs into the clinical development stage, proper moat being built

1 · Reply

NN555 Aug. 12 at 8:39 PM

$ABCL https://chatgpt.com/s/t_6a7cd9c7275081919a1cd812256604d3

1 · Reply

Bullock3000 Aug. 12 at 8:29 PM

$ABCL I just noticed this, curious: "No securities are being offered or sold, directly or indirectly, in Canada or to any resident of Canada."

2 · Reply

Bullock3000 Aug. 12 at 8:23 PM

$ABCL No offering statement released. Was it undersubscribed, they didnt offer it. What happened?

1 · Reply

psyxopathis Aug. 12 at 8:14 PM

$ABCL dont squeeze them PLEASE. this time, BURN THEM 🔥

0 · Reply

SwingTrades1 Aug. 12 at 8:14 PM

$ABCL Say hello to margin calls and forced short liquidations by brokers.

1 · Reply

cobracollect1 Aug. 12 at 8:10 PM

$ABCL

0 · Reply

daytwister1 Aug. 12 at 8:10 PM

$ABCL 13-14 $ by next week ? :)

0 · Reply

Vogelito Aug. 12 at 8:05 PM

$ABCL are you alive @tradersunion353 😵‍💫 You were talking about rewarding shareholders and it should go to 10-11 a couple of weeks ago?

1 · Reply

Estimize Aug. 12 at 8:03 PM

Wall St is expecting -0.17 EPS for $ABCL Q3 [Reporting 11/10 AMC] http://www.estimize.com/intro/abcl?chart=historical&metric_name=eps&utm_c

0 · Reply

Odoji Aug. 12 at 8:02 PM

$ABCL 💉

0 · Reply

Market Cap	2.86B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	14,848,000
Avg Vol	7,604,734
Day's Range	N/A - N/A
Shares Out	306.61M
Stochastic %K	89%
Beta	1.20
Analysts	Strong Sell
Price Target	$10.75